Meeting
2012 ASCO Annual Meeting
Sequential first-line treatment for metastatic colorectal cancer with capecitabine, irinotecan, and bevacizumab: Capecitabine plus bevacizumab (Cape-Bev) versus capecitabine, irinotecan plus bevacizumab (CAPIRI-Bev): The AIO KRK 0110 / ML22011 randomized, phase III trial.
Authors
Clemens Albrecht Giessen
Department of Hematology and Oncology, Klinikum Grosshadern and Comprehensive Cancer Center, LMU Munich, Munich, Germany
Clemens Albrecht Giessen , Dominik Paul Modest , Sebastian Stintzing , Ludwig Fischer von Weikersthal , Ursula Vehling-Kaiser , Ernst Spaeth-Schwalbe , Jens Freiberg-Richter , Julia Mayerle , Markus Bangerter , Claudio Denzlinger , Markus Sieber , Christian Teschendorf , Bettina Peuser , Volker Heinemann
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
NCT01249638
Citation
J Clin Oncol 30, 2012 (suppl; abstr TPS3639)
DOI
10.1200/jco.2012.30.15_suppl.tps3639
Abstract #
TPS3639
Poster Bd #
39D
Abstract Disclosures
Similar Posters
Poster
2013 Gastrointestinal Cancers Symposium
Bevacizumab (bev) in combination with capecitabine (cape) for the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC): Results of a randomized international phase III trial (AVEX).
First Author: David Cunningham
Poster
2024 ASCO Annual Meeting
Fruquintinib plus capecitabine versus capecitabine as first-line maintenance treatment of metastatic colorectal cancer (mCRC): Update results from the randomized, controlled, phase Ib/II study.
First Author: Wenhua Li
Poster
2022 ASCO Annual Meeting
Biweekly mXELIRI versus FOLFIRI in combination with bevacizumab as the first-line treatment for metastatic colorectal cancer (EXIST): A multicenter, randomized, open-label, phase 2 study.
First Author: Zhichao Jiang
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAF V600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz